Qyuns Therapeutics Announces Significant Investment in Wealth Management Products

Key Points from the Announcement

• Qyuns Therapeutics Co., Ltd. (Stock Code: 2509) has disclosed multiple transactions involving the subscription of wealth management products offered by Shanghai Pudong Development Bank (PDB).
• The company is deploying idle funds to maximize returns while maintaining liquidity and minimizing risk.
• Three major subscription agreements were executed in April and May 2026, with a combined principal amount of RMB270 million.
• An earlier subscription (March 2026) of RMB100 million is also aggregated with these transactions, making the total principal amount subscribed RMB370 million.
• All products are principal-guaranteed, floating-yield bank structured deposits with low risk ratings.
• This aggregation triggers discloseable transaction status under Hong Kong Listing Rules, requiring public notification.

Detailed Breakdown of the Wealth Management Product Subscriptions

Implications for Shareholders

• Strategic Capital Management: The subscriptions are part of Qyuns Therapeutics’ capital management initiative, aiming to enhance returns from idle cash while preserving liquidity and minimizing risk.
• Expected Yield: The structured deposits offer guaranteed yields with potential for additional floating yields, which can provide higher returns than conventional bank deposits.
• Risk Profile: All products are assessed as low risk, and the principal is guaranteed, reducing downside risk for the company.
• Shareholder Value: If the floating yield is realized at the higher range (up to 1.05% for some products), this could modestly boost the company’s profitability, supporting shareholder value.
• Listing Rules Compliance: Aggregating these subscriptions triggers “discloseable transaction” status under Hong Kong Listing Rules, signaling transparency and adherence to corporate governance standards.
• Financing Source: The investments are made with the company’s own funds, excluding proceeds from the IPO, indicating prudent use of surplus capital rather than dilution of shareholder equity.
• Internal Controls: The company emphasizes robust internal controls to ensure these investments do not affect working capital or daily operations.

Potential Price Sensitivity and Share Price Impact

While the investments are low risk and principal-guaranteed, the move reflects Qyuns Therapeutics’ proactive capital management strategy. The possibility of achieving floating yields up to 1.05% per annum (which is higher than typical commercial bank deposit rates) could incrementally enhance the company’s profitability. This may be viewed positively by investors, as it signals management’s commitment to maximizing shareholder returns from idle capital. Furthermore, the transparency and governance in aggregating and disclosing these transactions may reinforce market confidence. However, the absolute impact on share price will depend on broader market conditions and investor sentiment toward returns on cash management.

Company and Counterparty Information

• Qyuns Therapeutics Co., Ltd. is a leading biotech company in China, specializing in biologic therapies for autoimmune and allergic diseases, with a mature commercial-scale manufacturing capacity and a diversified drug pipeline.
• Shanghai Pudong Development Bank (PDB) is a reputable commercial bank listed on the Shanghai Stock Exchange, providing the structured deposit products subscribed by Qyuns Therapeutics.
• PDB and its ultimate beneficial owners are independent third parties, with no connection to Qyuns Therapeutics or its affiliates.

Board and Governance

• The Board is chaired by Mr. Qiu Jiwan, with a mix of executive, non-executive, and independent non-executive directors, underscoring strong governance and oversight of financial decisions.

Conclusion

Qyuns Therapeutics’ substantial investment in low-risk, principal-guaranteed structured deposits reflects prudent capital management and could marginally increase profitability. Investors should monitor the company’s yield realization and broader capital management strategy for future impacts on shareholder value. The transparency and compliance with listing rules further strengthen corporate governance and may bolster investor confidence.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should consider their own circumstances and consult with financial advisors before making investment decisions. The information is based on public disclosures as of April 29, 2026 and may be subject to change.

View QYUNS-B Historical chart here